Cheminformatics at the interface of medicinal chemistry and proteomics

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1844, Issue 1 PART A, 2014, Pages 156-161

  Koch, Uwe ^a   Hamacher, Michael ^a   Nussbaumer, Peter ^a  

^a Lead Discovery Center GmbH   (Germany)

Author keywords

Cheminformatics; Chemogenomics; Polypharmacology; Proteomics

Indexed keywords

LIGAND;

CONFORMATION; DRUG DESIGN; DRUG DEVELOPMENT; DRUG TARGETING; INFORMATION SCIENCE; LIGAND BINDING; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; REVIEW;

CHEMINFORMATICS; CHEMOGENOMICS; POLYPHARMACOLOGY; PROTEOMICS;

CHEMISTRY, PHARMACEUTICAL; DRUG DISCOVERY; PROTEOMICS;

EID: 84890427506     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2013.05.010     Document Type: Review

References (65)

1. M.A. Yildirim, K.I. Goh, M.E. Cusick, A.L. Barabasi, and M. Vidal Drug-target network Nat. Biotechnol. 25 2007 1119 1126
2. H. Yu, P. Braun, M.A. Yildirim, I. Lemmens, K. Venkatesan, J. Sahalie, T. Hirozane-Kishikawa, F. Gebreab, N. Li, N. Simonis, T. Hao, J.F. Rual, A. Dricot, A. Vazquez, R.R. Murray, C. Simon, L. Tardivo, S. Tam, N. Svrzikapa, C. Fan, A.S. de Smet, A. Motyl, M.E. Hudson, J. Park, X. Xin, M.E. Cusick, T. Moore, C. Boone, M. Snyder, F.P. Roth, A.L. Barabasi, J. Tavernier, D.E. Hill, and M. Vidal High-quality binary protein interaction map of the yeast interactome network Science 322 2008 104 110
3. G.V. Paolini, R.H. Shapland, W.P. van Hoorn, J.S. Mason, and A.L. Hopkins Global mapping of pharmacological space Nat. Biotechnol. 24 2006 805 815
4. J. Mestres, E. Gregori-Puigjane, S. Valverde, and R.V. Sole The topology of drug-target interaction networks: implicit dependence on drug properties and target families Mol. Biosyst. 5 2009 1051 1057
5. J.A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J.O. Park, N. Lindeman, C.M. Gale, X. Zhao, J. Christensen, T. Kosaka, A.J. Holmes, A.M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B.E. Johnson, L.C. Cantley, and P.A. Janne MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043
6. Y.Y. Janjigian, C.G. Azzoli, L.M. Krug, L.K. Pereira, N.A. Rizvi, M.C. Pietanza, M.G. Kris, M.S. Ginsberg, W. Pao, V.A. Miller, and G.J. Riely Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib Clin. Cancer Res. 17 2011 2521 2527
7. W. Pao, V.A. Miller, K.A. Politi, G.J. Riely, R. Somwar, M.F. Zakowski, M.G. Kris, and H. Varmus Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2 2005 e73
8. N.V. Sergina, M. Rausch, D. Wang, J. Blair, B. Hann, K.M. Shokat, and M.M. Moasser Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 Nature 445 2007 437 441
9. M.L. Sos, M. Koker, B.A. Weir, S. Heynck, R. Rabinovsky, T. Zander, J.M. Seeger, J. Weiss, F. Fischer, P. Frommolt, K. Michel, M. Peifer, C. Mermel, L. Girard, M. Peyton, A.F. Gazdar, J.D. Minna, L.A. Garraway, H. Kashkar, W. Pao, M. Meyerson, and R.K. Thomas PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR Cancer Res. 69 2009 3256 3261
10. D. Plewczynski, S.A. Spieser, and U. Koch Assessing different classification methods for virtual screening J. Chem. Inf. Model. 46 2006 1098 1106
11. D. Plewczynski, G.M. von, S.A. Spieser, L. Rychlewski, L.S. Wyrwicz, K. Ginalski, and U. Koch Target specific compound identification using a support vector machine Comb. Chem. High Throughput Screen. 10 2007 189 196
12. M. Johnson, M. Lajiness, and G. Maggiora Molecular similarity: a basis for designing drug screening programs Prog. Clin. Biol. Res. 291 1989 167 171
13. G.M. Maggiora, and V. Shanmugasundaram Molecular similarity measures Methods Mol. Biol. 672 2011 39 100
14. J. Duan, S.L. Dixon, J.F. Lowrie, and W. Sherman Analysis and comparison of 2D fingerprints: insights into database screening performance using eight fingerprint methods J. Mol. Graph. Model. 29 2010 157 170
15. D.J. Wild, and C.J. Blankley Comparison of 2D fingerprint types and hierarchy level selection methods for structural grouping using Ward's clustering J. Chem. Inf. Comput. Sci. 40 2000 155 162
16. P.C. Hawkins, A.G. Skillman, and A. Nicholls Comparison of shape-matching and docking as virtual screening tools J. Med. Chem. 50 2007 74 82
17. T.S. Rush III, J.A. Grant, L. Mosyak, and A. Nicholls A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction J. Med. Chem. 48 2005 1489 1495
18. G.W. Bemis, and M.A. Murcko The properties of known drugs. 1. Molecular frameworks J. Med. Chem. 39 1996 2887 2893
19. G.W. Bemis, and M.A. Murcko Properties of known drugs. 2. Side chains J. Med. Chem. 42 1999 5095 5099
20. S. Renner, W.A. van Otterlo, S.M. Dominguez, S. Mocklinghoff, B. Hofmann, S. Wetzel, A. Schuffenhauer, P. Ertl, T.I. Oprea, D. Steinhilber, L. Brunsveld, D. Rauh, and H. Waldmann Bioactivity-guided mapping and navigation of chemical space Nat. Chem. Biol. 5 2009 585 592
21. A. Schuffenhauer, P. Ertl, S. Roggo, S. Wetzel, M.A. Koch, and H. Waldmann The scaffold tree - visualization of the scaffold universe by hierarchical scaffold classification J. Chem. Inf. Model. 47 2007 47 58
22. S. Wetzel, K. Klein, S. Renner, D. Rauh, T.I. Oprea, P. Mutzel, and H. Waldmann Interactive exploration of chemical space with Scaffold Hunter Nat. Chem. Biol. 5 2009 696
23. Y. Hu, and J. Bajorath Polypharmacology directed compound data mining: identification of promiscuous chemotypes with different activity profiles and comparison to approved drugs J. Chem. Inf. Model. 50 2010 2112 2118
24. Y. Hu, A.M. Wassermann, E. Lounkine, and J. Bajorath Systematic analysis of public domain compound potency data identifies selective molecular scaffolds across druggable target families J. Med. Chem. 53 2010 752 800
25. M.J. Keiser, B.L. Roth, B.N. Armbruster, P. Ernsberger, J.J. Irwin, and B.K. Shoichet Relating protein pharmacology by ligand chemistry Nat. Biotechnol. 25 2007 197 206
26. M.J. Keiser, V. Setola, J.J. Irwin, C. Laggner, A.I. Abbas, S.J. Hufeisen, N.H. Jensen, M.B. Kuijer, R.C. Matos, T.B. Tran, R. Whaley, R.A. Glennon, J. Hert, K.L. Thomas, D.D. Edwards, B.K. Shoichet, and B.L. Roth Predicting new molecular targets for known drugs Nature 462 2009 175 181
27. E. Lounkine, M.J. Keiser, S. Whitebread, D. Mikhailov, J. Hamon, J.L. Jenkins, P. Lavan, E. Weber, A.K. Doak, S. Cote, B.K. Shoichet, and L. Urban Large-scale prediction and testing of drug activity on side-effect targets Nature 486 2012 361 367
28. A. Gaulton, L.J. Bellis, A.P. Bento, J. Chambers, M. Davies, A. Hersey, Y. Light, S. McGlinchey, D. Michalovich, B. Al-Lazikani, and J.P. Overington ChEMBL: a large-scale bioactivity database for drug discovery Nucleic Acids Res. 40 2012 D1100 D1107
29. E. Gregori-Puigjane, V. Setola, J. Hert, B.A. Crews, J.J. Irwin, E. Lounkine, L. Marnett, B.L. Roth, and B.K. Shoichet Identifying mechanism-of-action targets for drugs and probes Proc. Natl. Acad. Sci. U. S. A. 109 2012 11178 11183
30. C. Laggner, D. Kokel, V. Setola, A. Tolia, H. Lin, J.J. Irwin, M.J. Keiser, C.Y. Cheung, D.L. Minor Jr., B.L. Roth, R.T. Peterson, and B.K. Shoichet Chemical informatics and target identification in a zebrafish phenotypic screen Nat. Chem. Biol. 8 2012 144 146
31. T. Noeske, B.C. Sasse, H. Stark, C.G. Parsons, T. Weil, and G. Schneider Predicting compound selectivity by self-organizing maps: cross-activities of metabotropic glutamate receptor antagonists Chem. Med. Chem. 1 2006 1066 1068
32. S.R. Vasudevan, J.B. Moore, Y. Schymura, and G.C. Churchill Shape-based reprofiling of FDA-approved drugs for the H(1) histamine receptor J. Med. Chem. 2012 7054 7060
33. A. Nicholls, and J.A. Grant Molecular shape and electrostatics in the encoding of relevant chemical information J. Comput. Aided Mol. Des. 19 2005 661 686
34. A. Nicholls, G.B. McGaughey, R.P. Sheridan, A.C. Good, G. Warren, M. Matthieu, S.W. Muchmore, S.P. Brown, J.A. Grant, J.A. Haigh, N. Nevins, A.N. Jain, and B. Kelley Molecular shape and medicinal chemistry: a perspective J. Med. Chem. 53 2010 3862 3886
35. F. Iorio, T. Rittman, H. Ge, M. Menden, and J. Saez-Rodriguez Transcriptional data: a new gateway to drug repositioning? Drug Discov. Today 18 2013 350 357
36. M. Bieler, R. Heilker, H. Koppen, and G. Schneider Assay Related Target Similarity (ARTS) - chemogenomics approach for quantitative comparison of biological targets J. Chem. Inf. Model. 51 2011 1897
37. M. Bieler, R. Heilker, H. Koppen, and G. Schneider Assay Related Target Similarity (ARTS) - chemogenomics approach for quantitative comparison of biological targets J. Chem. Inf. Model. 51 2011 1897 1905
38. T. Cheng, Q. Li, Y. Wang, and S.H. Bryant Identifying compound-target associations by combining bioactivity profile similarity search and public databases mining J. Chem. Inf. Model. 51 2011 2440 2448
39. F.C. Bernstein, T.F. Koetzle, G.J. Williams, E.F. Meyer Jr., M.D. Brice, J.R. Rodgers, O. Kennard, T. Shimanouchi, and M. Tasumi The Protein Data Bank: a computer-based archival file for macromolecular structures Arch. Biochem. Biophys. 185 1978 584 591
40. C. Knox, V. Law, T. Jewison, P. Liu, S. Ly, A. Frolkis, A. Pon, K. Banco, C. Mak, V. Neveu, Y. Djoumbou, R. Eisner, A.C. Guo, and D.S. Wishart DrugBank 3.0: a comprehensive resource for 'omics' research on drugs Nucleic Acids Res. 39 2011 D1035 D1041
41. E.L. Willighagen, A. Waagmeester, O. Spjuth, P. Ansell, A.J. Williams, V. Tkachenko, J. Hastings, B. Chen, and D.J. Wild The Chembl database as linked open data J. Cheminform. 5 2013 23
42. Y. Wang, J. Xiao, T.O. Suzek, J. Zhang, J. Wang, Z. Zhou, L. Han, K. Karapetyan, S. Dracheva, B.A. Shoemaker, E. Bolton, A. Gindulyte, and S.H. Bryant PubChem's BioAssay database Nucleic Acids Res. 40 2012 D400 D412
43. J. Lamb, E.D. Crawford, D. Peck, J.W. Modell, I.C. Blat, M.J. Wrobel, J. Lerner, J.P. Brunet, A. Subramanian, K.N. Ross, M. Reich, H. Hieronymus, G. Wei, S.A. Armstrong, S.J. Haggarty, P.A. Clemons, R. Wei, S.A. Carr, E.S. Lander, and T.R. Golub The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease Science 313 2006 1929 1935
44. F. Iorio, R. Tagliaferri, and B.D. di Identifying network of drug mode of action by gene expression profiling J. Comput. Biol. 16 2009 241 251
45. F. Iorio, R. Bosotti, E. Scacheri, V. Belcastro, P. Mithbaokar, R. Ferriero, L. Murino, R. Tagliaferri, N. Brunetti-Pierri, A. Isacchi, and B.D. di Discovery of drug mode of action and drug repositioning from transcriptional responses Proc. Natl. Acad. Sci. U. S. A. 107 2010 14621 14626
46. J.T. Dudley, M. Sirota, M. Shenoy, R.K. Pai, S. Roedder, A.P. Chiang, A.A. Morgan, M.M. Sarwal, P.J. Pasricha, and A.J. Butte Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease Sci. Transl. Med. 3 2011 96ra76
47. B.Y. Feng, A. Simeonov, A. Jadhav, K. Babaoglu, J. Inglese, B.K. Shoichet, and C.P. Austin A high-throughput screen for aggregation-based inhibition in a large compound library J. Med. Chem. 50 2007 2385 2390
48. A. Jadhav, R.S. Ferreira, C. Klumpp, B.T. Mott, C.P. Austin, J. Inglese, C.J. Thomas, D.J. Maloney, B.K. Shoichet, and A. Simeonov Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease J. Med. Chem. 53 2010 37 51
49. J. Seidler, S.L. McGovern, T.N. Doman, and B.K. Shoichet Identification and prediction of promiscuous aggregating inhibitors among known drugs J. Med. Chem. 46 2003 4477 4486
50. J.B. Baell, and G.A. Holloway New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays J. Med. Chem. 53 2010 2719 2740
51. J.B. Baell Observations on screening-based research and some concerning trends in the literature Future Med. Chem. 2 2010 1529 1546
52. J. Che, F.J. King, B. Zhou, and Y. Zhou Chemical and biological properties of frequent screening hits J. Chem. Inf. Model. 52 2012 913 926
53. H. Strombergsson, A. Kryshtafovych, P. Prusis, K. Fidelis, J.E. Wikberg, J. Komorowski, and T.R. Hvidsten Generalized modeling of enzyme-ligand interactions using proteochemometrics and local protein substructures Proteins 65 2006 568 579
54. G.J. van Westen, J.K. Wegner, P. Geluykens, L. Kwanten, I. Vereycken, A. Peeters, A.P. IJzerman, H.W. van Vlijmen, and A. Bender Which compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical development PLoS One 6 2011 e27518
55. A.M. Wassermann, H. Geppert, and J. Bajorath Ligand prediction for orphan targets using support vector machines and various target-ligand kernels is dominated by nearest neighbor effects J. Chem. Inf. Model. 49 2009 2155 2167
56. N. Weill, and D. Rognan Development and validation of a novel protein-ligand fingerprint to mine chemogenomic space: application to G protein-coupled receptors and their ligands J. Chem. Inf. Model. 49 2009 1049 1062
57. N. Weill Chemogenomic approaches for the exploration of GPCR space Curr. Top. Med. Chem. 11 2011 1944 1955
58. J. Meslamani, and D. Rognan Enhancing the accuracy of chemogenomic models with a three-dimensional binding site kernel J. Chem. Inf. Model. 51 2011 1593 1603
59. V. Cappello, A. Tramontano, and U. Koch Classification of proteins based on the properties of the ligand-binding site: the case of adenine-binding proteins Proteins 47 2002 106 115
60. A. Weber, A. Casini, A. Heine, D. Kuhn, C.T. Supuran, A. Scozzafava, and G. Klebe Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition J. Med. Chem. 47 2004 550 557
61. R. Najmanovich, N. Kurbatova, and J. Thornton Detection of 3D atomic similarities and their use in the discrimination of small molecule protein-binding sites Bioinformatics 24 2008 i105 i111
62. F. Milletti, and A. Vulpetti J. Chem. Inf. Model. 50 2010 1418 1431
63. O.V. Kalinina, O. Wichmann, G. Apic, and R.B. Russell Combinations of protein-chemical complex structures reveal new targets for established drugs PLoS Comput. Biol. 7 2011 e1002043
64. O.V. Kalinina, O. Wichmann, G. Apic, and R.B. Russell ProtChemSI: a network of protein-chemical structural interactions Nucleic Acids Res. 40 2012 D549 D553
65. S.L. Kinnings, N. Liu, N. Buchmeier, P.J. Tonge, L. Xie, and P.E. Bourne Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis PLoS Comput. Biol. 5 2009 e1000423